These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 26285242)

  • 21. Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience.
    Correale P; Cusi MG; Micheli L; Nencini C; Del Vecchio MT; Torino F; Aquino A; Bonmassar E; Francini G; Giorgi G
    Invest New Drugs; 2006 Mar; 24(2):99-110. PubMed ID: 16502353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
    Kather JN; Halama N; Jaeger D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gut Microbiome: A Promising Biomarker for Immunotherapy in Colorectal Cancer.
    Temraz S; Nassar F; Nasr R; Charafeddine M; Mukherji D; Shamseddine A
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Development of immune checkpoint inhibitor in colorectal cancer].
    Kitano S
    Nihon Rinsho; 2016 Nov; 74(11):1818-1820. PubMed ID: 30550688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-operative interleukin-2 immunotherapy induces eosinophilic infiltration in colorectal neoplastic stroma.
    Bovo G; Brivio F; Brenna A; Fumagalli L; Perego P; Brivio O; Uggeri F; Lavorato F; Bratina G
    Pathologica; 1995 Apr; 87(2):135-8. PubMed ID: 8532404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T-cell-based immunotherapy in colorectal cancer.
    Feng M; Zhao Z; Yang M; Ji J; Zhu D
    Cancer Lett; 2021 Feb; 498():201-209. PubMed ID: 33129958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma.
    Li X; Nie J; Mei Q; Han WD
    World J Gastroenterol; 2016 Jun; 22(23):5317-31. PubMed ID: 27340348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Chemo- and immunotherapy of colorectal cancer].
    Klein HO
    Internist (Berl); 1991 Jun; 32(6):348-53. PubMed ID: 1880013
    [No Abstract]   [Full Text] [Related]  

  • 30. Immune checkpoints and immunotherapy for colorectal cancer.
    Singh PP; Sharma PK; Krishnan G; Lockhart AC
    Gastroenterol Rep (Oxf); 2015 Nov; 3(4):289-97. PubMed ID: 26510455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review on the immunotherapy strategies against metastatic colorectal carcinoma.
    Signorini L; Delbue S; Ferrante P; Bregni M
    Immunotherapy; 2016 Oct; 8(10):1245-61. PubMed ID: 27605072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges.
    Link JT; Overman MJ
    Cancer J; 2016; 22(3):190-5. PubMed ID: 27341597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
    Monteiro ID; Califano R; Mountzios G; de Mello RA
    Future Oncol; 2016 Feb; 12(4):551-64. PubMed ID: 26776915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy for colorectal cancer: where are we heading?
    Basile D; Garattini SK; Bonotto M; Ongaro E; Casagrande M; Cattaneo M; Fanotto V; De Carlo E; Loupakis F; Urbano F; Negri FV; Pella N; Russano M; Brunetti O; Scartozzi M; Santini D; Silvestris N; Casadei Gardini A; Puzzoni M; Calvetti L; Cardarelli N; Aprile G
    Expert Opin Biol Ther; 2017 Jun; 17(6):709-721. PubMed ID: 28375039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins.
    Shapira S; Lisiansky V; Arber N; Kraus S
    Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S67-77. PubMed ID: 20374033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.
    Elsaleh H; Iacopetta B
    Clin Colorectal Cancer; 2001 Aug; 1(2):104-9. PubMed ID: 12445368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy for metastatic colorectal cancer: present status and new options.
    Ellebaek E; Andersen MH; Svane IM; Straten PT
    Scand J Gastroenterol; 2012 Mar; 47(3):315-24. PubMed ID: 22214467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The evolving role of immune oncology in colorectal cancer.
    Dawood S
    Chin Clin Oncol; 2018 Apr; 7(2):17. PubMed ID: 29764162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy of colorectal cancer: new perspectives after a long path.
    Correale P; Botta C; Ciliberto D; Pastina P; Ingargiola R; Zappavigna S; Tassone P; Pirtoli L; Caraglia M; Tagliaferri P
    Immunotherapy; 2016 Nov; 8(11):1281-1292. PubMed ID: 27993089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer.
    Zhen YH; Liu XH; Yang Y; Li B; Tang JL; Zeng QX; Hu J; Zeng XN; Zhang L; Wang ZJ; Li XY; Ge HX; Winqvist O; Hu PS; Xiu J
    Cancer Immunol Immunother; 2015 Sep; 64(9):1083-93. PubMed ID: 25990075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.